Emerging Role of Weight-Loss Medications Post-Bariatric Surgery in Reducing Heart Disease Risk
New research suggests that weight-loss medications like semaglutide and liraglutide may reduce cardiovascular risk in patients post-bariatric surgery, especially those not achieving optimal weight or diabetes control.
Recent research presented at the European Congress on Obesity highlights the potential cardiovascular benefits of popular weight-loss drugs, such as semaglutide and liraglutide, in adults who have undergone bariatric surgery. These medications may be particularly beneficial for individuals who do not achieve sufficient weight loss or diabetes control following surgery, by further lowering the risk of major adverse cardiovascular events (MACE) like heart attacks and strokes, as well as reducing mortality.
The observational study involved adults with obesity and type 2 diabetes but no prior cardiovascular disease, analyzing data from over 4.8 million patients covered by Clalit Health Services in Israel. Among the 822 participants (average age 58, predominantly female), those treated with GLP-1 receptor agonists (GLP-1 RAs), mainly semaglutide and liraglutide, after surgery showed a 67% lower risk of MACE or death compared to those who only had bariatric surgery.
Initially, patients started with higher weight and blood glucose levels, but over time, these metrics declined and aligned with those who experienced successful surgical outcomes. The treatment involved weekly injections that mimic natural incretin hormones, which help lower blood sugar, slow digestion, and promote satiety.
This research fills a crucial knowledge gap regarding the role of GLP-1 RAs in primary prevention of cardiovascular events post-bariatric surgery. While the findings are promising, the study's limitations include a small sample size, and further extensive clinical trials are necessary to validate these results and determine optimal timing for intervention.
The study underscores the potential of combining pharmacotherapy with surgical approaches to optimize long-term health outcomes for individuals battling obesity and diabetes. As obesity rates continue to rise globally, integrating these treatments could become a key strategy in reducing cardiovascular risks associated with obesity and metabolic disorders.
Source: medicalXpress
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Evaluating the Real-World Impact of Bevacizumab in Ovarian Cancer Treatment
A new study examines the real-world effectiveness of bevacizumab added to chemotherapy for ovarian cancer, highlighting benefits in high-risk patient groups and informing personalized treatment strategies.
